Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Farnebo Marianne) > (2020-2023) > Evaluation of dyske...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04964naa a2200553 4500
001		oai:DiVA.org:oru-95773
003		SwePub
008		211207s2022 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:prod.swepub.kib.ki.se:148270346
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-957732 URI
024	7	a https://doi.org/10.3892/ol.2021.131482 DOI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1482703462 URI
040		a (SwePub)orud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Ranhem, Ceciliau Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Region Västmanland, Uppsala University, Västmanlands Hospital Västerås, Västerås, Sweden4 aut
245	1 0	a Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma
264		c 2021-11-23
264	1	b Spandidos Publications,c 2022
338		a print2 rdacarrier
500		a Funding agencies:Karolinska Institute Cancer Strategic Grants 5888-05722Gustaf V Jubilee Fund 154022 151202 Centre of Clinical Research, Västmanland County Council LTV-940144
520		a Primary vaginal cancer (PVC) is a rare gynaecological malignancy, which, at present, lacks appropriate biomarkers for prognosis. The proteins dyskerin and WD repeat containing antisense to TP53 (WRAP53β), both of which exert their functions in the telomerase holoenzyme complex, have been shown to be upregulated in different cancer types. These proteins have also been proposed as prognostic markers in some types of cancer. The aim of the present study was to examine the expression patterns of dyskerin and WRAP53β in patients with PVC. Moreover, as part of a search for effective biomarkers to evaluate prognosis in PVC, the expression of these two proteins and their potential association with clinical variables and survival were also evaluated. The expression of dyskerin and WRAP53β was assessed in PVC tumour samples from 68 patients using immunohistochemistry. The majority of tumour samples showed low and moderate expression levels of dyskerin. Upregulation of dyskerin in tumour samples was significantly associated with a shorter survival time and a poorer cancer-specific survival rate. WRAP53β was also expressed in most of the cells but was not significantly associated with clinical variables or survival. This study demonstrates that upregulation of dyskerin is significantly associated with poor prognosis. Thus, dyskerin may serve as a promising prognostic marker and a potential putative therapeutic target in PVC.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653		a Cajal body
653		a WRAP53β
653		a biomarker
653		a dyskerin
653		a primary vaginal carcinoma
653		a prognosis
653		a survival
700	1	a Lillsunde-Larsson, Gabriella,d 1971-u Örebro universitet,Institutionen för hälsovetenskaper,Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden4 aut0 (Swepub:oru)geln
700	1	a Lindqvist, Davidu Department of Radiation Sciences, Umeå Universitet, Umeå, Sweden4 aut
700	1	a Sorbe, Bengtu Department of Oncology, Örebro University Hospital, Örebro, Sweden4 aut
700	1	a Karlsson, Mats,d 1960-u Örebro universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:oru)mskn
700	1	a Farnebo, Marianneu Karolinska Institutet4 aut
700	1	a Hellman, Kristinau Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden4 aut
700	1	a Kovaleska, Larysau R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine, Kiev, Ukraine4 aut
700	1	a Kashuba, Elenau Karolinska Institutet4 aut
700	1	a Andersson, Soniau Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden4 aut
710	2	a Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Region Västmanland, Uppsala University, Västmanlands Hospital Västerås, Västerås, Swedenb Institutionen för hälsovetenskaper4 org
773	0	t Oncology Lettersd : Spandidos Publicationsg 23:1q 23:1x 1792-1074x 1792-1082
856	4	u https://doi.org/10.3892/ol.2021.13148y Fulltext
856	4	u https://www.spandidos-publications.com/10.3892/ol.2021.13148/download
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-95773
856	4 8	u https://doi.org/10.3892/ol.2021.13148
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:148270346

Hitta via bibliotek

Oncology Letters (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Ranhem, Cecilia; Lillsunde-Larsso ...; Lindqvist, David; Sorbe, Bengt; Karlsson, Mats, ...; Farnebo, Mariann ...; visa fler...; Hellman, Kristin ...; Kovaleska, Larys ...; Kashuba, Elena; Andersson, Sonia; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Oncology Letters

Av lärosätet: Örebro universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se